JP2022540768A5 - - Google Patents

Info

Publication number
JP2022540768A5
JP2022540768A5 JP2021576605A JP2021576605A JP2022540768A5 JP 2022540768 A5 JP2022540768 A5 JP 2022540768A5 JP 2021576605 A JP2021576605 A JP 2021576605A JP 2021576605 A JP2021576605 A JP 2021576605A JP 2022540768 A5 JP2022540768 A5 JP 2022540768A5
Authority
JP
Japan
Prior art keywords
cells
macrophages
bone marrow
regulated
marrow cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021576605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038116 external-priority patent/WO2020263651A1/en
Publication of JP2022540768A publication Critical patent/JP2022540768A/ja
Publication of JP2022540768A5 publication Critical patent/JP2022540768A5/ja
Pending legal-status Critical Current

Links

JP2021576605A 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用 Pending JP2022540768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867602P 2019-06-27 2019-06-27
US62/867,602 2019-06-27
PCT/US2020/038116 WO2020263651A1 (en) 2019-06-27 2020-06-17 Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (2)

Publication Number Publication Date
JP2022540768A JP2022540768A (ja) 2022-09-20
JP2022540768A5 true JP2022540768A5 (enExample) 2023-06-26

Family

ID=74060343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576605A Pending JP2022540768A (ja) 2019-06-27 2020-06-17 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用

Country Status (10)

Country Link
US (1) US20220251233A1 (enExample)
EP (1) EP3990015A4 (enExample)
JP (1) JP2022540768A (enExample)
KR (1) KR20220042128A (enExample)
CN (1) CN114728057A (enExample)
AU (1) AU2020304415A1 (enExample)
BR (1) BR112021026181A2 (enExample)
CA (1) CA3142840A1 (enExample)
IL (1) IL289171A (enExample)
WO (1) WO2020263651A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102616360B1 (ko) * 2021-11-09 2023-12-27 재단법인 아산사회복지재단 염증성 근육병증 진단용 바이오마커 조성물
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
CN117816128B (zh) * 2023-12-15 2025-11-25 华南农业大学 一种重金属检测-吸附一体化复合材料及其制备方法与应用
JP7720659B1 (ja) * 2024-11-15 2025-08-08 宜広 磯貝 骨感染症の血漿バイオマーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504186A (ja) * 1990-07-13 1994-05-19 ザ ジェネラル ホスピタル コーポレイション Ｃｄ５３細胞表面抗原とその使用
WO2002072861A1 (en) * 2001-03-08 2002-09-19 Incyte Genomics, Inc. Cd53 cell surface antigen
US7674598B2 (en) * 2004-05-21 2010-03-09 Beckman Coulter, Inc. Method for a fully automated monoclonal antibody-based extended differential
EP2041299A4 (en) * 2006-07-14 2010-01-13 Aviva Biosciences Corp METHOD AND COMPOSITIONS FOR DETECTION OF RARE CELLS FROM A BIOLOGICAL SAMPLE
WO2017068164A1 (en) * 2015-10-21 2017-04-27 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
EP3452510A4 (en) * 2016-04-04 2020-01-15 Bioverativ USA Inc. ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF
BR112019002035A2 (pt) * 2016-08-01 2019-05-14 Novartis Ag tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
JP7369121B2 (ja) * 2017-10-11 2023-10-25 バイオベラティブ・ユーエスエイ・インコーポレイテッド 補体活性を誘発する方法
EP3813881A4 (en) * 2018-06-29 2022-09-14 Verseau Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF MONOCYTE AND MACROPHAGE INFLAMMATION PHENOTYPES AND IMMUNOTHERAPY USES THEREOF

Similar Documents

Publication Publication Date Title
JP2022535417A5 (enExample)
JP2022535550A5 (enExample)
JP2022540768A5 (enExample)
JP7305704B2 (ja) Ｔ細胞療法のための診断方法
ES2961666T3 (es) Métodos para determinar la dosificación de células CAR-T
JP2024059707A (ja) 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療
JP2021165291A (ja) Ｔ細胞療法のために患者をコンディショニングする方法
US20220169694A1 (en) Chimeric antigen receptor t cell therapy
WO2019109053A1 (en) Methods for dosing and for modulation of genetically engineered cells
JP2023527410A5 (enExample)
JP2019517773A (ja) 抗ｌａｇ−３抗体
JP2020512983A (ja) 最適化された多機能性ｔ細胞を含むキメラ受容体ｔ細胞を使用する治療
US20250313855A1 (en) Chimeric antigen receptor t cell therapy
US12357646B2 (en) Chimeric antigen receptor T cell therapy
TW202238129A (zh) Ｔ細胞療法
KR20190117014A (ko) 방광암의 항-pd-l1 항체 치료
KR20230137402A (ko) 면역요법 선택을 위한 유전자 마커
KR20240144434A (ko) 면역요법으로 인한 유해사례 예측
JP2022539038A5 (enExample)
WO2019089858A2 (en) Methods of assessing or monitoring a response to a cell therapy
JP2023501487A (ja) 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用
US20240158869A1 (en) Factors for optimizing immunotherapy
US20250161361A1 (en) Factors for optimizing immunotherapy efficacy
JP2026510915A (ja) 免疫療法の有効性に対する腫瘍微小環境の影響
JP2026071229A (ja) 免疫療法由来の有害事象の予測